7. Fuchs, P. C., Jones, R. N., Barry, A. L., Thornsberry, C.: Evaluation of the *in vitro* activity of BMY-28142, a new broad-spectrum cephalosporin. *Antimicrob. Agents Chemother.* 27 (1985) 679–682.
8. Clarke, A. M., Zemcov, S. J. V., Wright, J. M.: HR 810 and BMY-28142, two new cephalosporins with broad-spectrum activity: an *in-vitro* comparison with other β -lactam antibiotics. *J. Antimicrob. Chemother.* 15 (1985) 305–310.
9. Tsuji, A., Maniatis, A., Bertram, M. A., Young, L. S.: *In vitro* activity of BMY-28142 in comparison with those of other β -lactam antimicrobial agents. *Antimicrob. Agents Chemother.* 27 (1985) 515–519.
10. Kessler, R. E., Bies, M., Buck, R. E., Chisholm, D. R., Pursiano, T. A., Tsai, Y. H., Misiek, M., Price, K. E., Leitner, F.: Comparison of a new cephalosporin, BMY-28142, with other broad-spectrum β -lactam antibiotics. *Antimicrob. Agents Chemother.* 27 (1985) 207–216.
11. Kropec, A., Daschner, F.: *In vitro* activity of fleroxacin on 6 other antimicrobials against *Acinetobacter anitratus*. *Chemotherapy* 35 (1989) 360–362.
12. Voutsinas, D., Mavroudis, T., Avlami, A., Giamarellou, H.: Comparative *in vitro* activity of cefepime (BMY 28142) against multiresistant nosocomial isolates of *Pseudomonas aeruginosa*. *Eur. J. Clin. Microbiol. Infect. Dis.* 8 (1989) 917–919.
13. Vuys, A., Pijck, J.: *In vitro* antibacterial activity of BMY-28142, a new extended-spectrum cephalosporin. *Antimicrob. Agents Chemother.* 27 (1985) 574–577.
14. Barbhuiya, R. H., Forgue, S. T., Gleason, C. R., Knupp, C. A., Pittmann, K. A., Weidler, D. J., Martin, R. R.: Safety, tolerance, and pharmacokinetic evaluation of cefepime after administration of single intravenous doses. *Antimicrob. Agents Chemother.* 34 (1990) 1118–1122.
15. Phleps, D. J., Carlton, D. D., Farrell, C. A., Kessler, R. E.: Affinity of cephalosporins for β -lactamases as a factor in antibacterial efficacy. *Antimicrob. Agents Chemother.* 29 (1986) 845–848.
16. Knapp, C. C., Washington, J. A.: Activity of cefepime, ceftazidime, and ceftizoxime against mutants of enterobacteriaceae and *Pseudomonas aeruginosa* derepressed for class I β -lactamases. *J. Antimicrob. Chemother.* 24 (1989) 1011–1018.
17. Fung-Tomc, J., Dougherty, T. J., DeDorio, F. J., Simich-Jacobson, V., Kessler, R. E.: Activity of cefepime against ceftazidime- and cefotaxime-resistant gram-negative bacteria and its relationship to β -lactamase levels. *Antimicrob. Agents Chemother.* 33 (1989) 498–502.
18. Jones, R. N., Fuchs, P. C.: Activity of cefepime (BMY-28142) and cefpirome (HR 810) against gram-negative bacilli resistant to cefotaxime or ceftazidime. *J. Antimicrob. Chemother.* 23 (1989) 163–165.
19. Iwahi, T., Nakao, M., Okonogi, K., Noji, Y., Yamazaki, T., Imada, A.: SCE-2787, a new parenteral cephalosporin: *in vitro* antibacterial activity. 29th ICAAC (1989), Abstr. 489.
20. Nishino, T., Otsuki, M., Noji, Y., Tsuchimori, N.: *In vitro* and *in vivo* antibacterial activities of SCE-2787, a new parenteral cephalosporin. 29th ICAAC (1989), Abstr. 490.
21. Nakane, T., Inoue, M., Mitsuhashi, S.: Antibacterial activity of SCE-2787, a new β -lactamase-stable parenteral cephalosporin. 29th ICAAC (1989), Abstr. 487.
22. Goto, S., Miyazaki, S., Kaneko, Y., Tsuji, A., Kuwahara, S.: *In vitro* antibacterial activity of SCE-2787, a new parenteral cephalosporin. 29th ICAAC (1989), Abstr. 488.

Erratum

Infection 19 (1991) No. 1

J. Kohler et al.: "Listeria Brainstem Encephalitis: Two Own Cases and Literature Review", pages 36–40.

On pages 37 and 38 the legends of Figures 1 and 2 were exchanged by mistake.